ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
98,194.61
0.09%
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs Yen
157.205
0.01%
Brent Oil
76.495
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) ニュース

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MDGL
日付受信時刻ニュースソース見出しコード企業名
2025/01/0322 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/2306 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/2206 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/1506 : 00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/1420 : 30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0907 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0806 : 36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0622 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor ConferencesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0609 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0205 : 47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/11/0105 : 32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/3122 : 02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/3120 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/3120 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/3021 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/2121 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH CirrhosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/1821 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/0221 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/10/0121 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical DevelopmentNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/09/3021 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/09/1210 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/09/1110 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/2621 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/2009 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/1608 : 52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/0721 : 58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/0720 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/0720 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/08/0220 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Shannon Kelley as General CounselNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/07/2421 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL

最近閲覧した銘柄

FX
USDEUR
US Dollar vs Euro
NYSE
DIS
Walt Disney
AMEX
SPY
SPDR S&P 500
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
CCOM
SILVER
SILVER
NYSE
KO
Coca Cola
FX
USDJPY
US Dollar vs Yen
NYSE
MCD
McDonalds
COIN
AVAXUSD
Avalanche
AMEX
XLF
Financial Select Sector
COIN
ADAUSD
Cardano
NYSE
BAC
Bank of America
USOTC
ADDYY
Adidas (QX)
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有